The Pharmaceutical Journal
Vol 270 No 7240 p355
15 March 2003

This article
Reprint
Photocopy

News summary

Related websites
BMJ abstract (more)

Cost analysis for MS drugs

A cost effectiveness analysis performed for the National Institute for Clinical Excellence, for its appraisal of therapies for multiple sclerosis has been published (BMJ 2003;326:522). The researchers show that the cost per quality adjusted life year of interferon betas and glatiramer is unlikely to be less than £40,000.